Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphona

Leukemia and Lymphoma

Volumn 48, Issue 4, 2007, Pages 716-722

  Park, Byeong Bae ^a   Ryoo, Baek Yeol ^b   Lee, Jae H ^c   Kwon, Hyuck C ^d   Yang, Sung H ^b   Kang, Hye J ^b   Kim, Hyo J ^d   Oh, Sung Y ^d   Ko, Young H ^a   Huh, Joo R ^e   Lee, Seung S ^b   Nam, Eun M ^c   Park, Keon W ^f   Kim, Jung H ^g   Kang, Jung H ^h   Bang, Soo M ⁱ   Park, Sarah ^a   Kim, Kihyun ^a   Park, Keunchil ^a   Suh, Cheolwon ^e   Kim, Won S ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

^c Gachon University   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Dankook University   (South Korea)

^g Hallym University   (South Korea)

^h Gyeongsang National University   (South Korea)

ⁱ Seoul National University Bundang Hospital   (South Korea)

Author keywords

Angioimmunoblastic T cell lymphoma; Clinical features; Treatment outcomes

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGE DETERMINATION; AGED; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; CHEMOTHERAPY; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG MEGADOSE; ELECTROCORTICOGRAPHY; FEMALE; FEVER; GAMMOPATHY; HUMAN; HUMAN TISSUE; JAUNDICE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RASH; SALVAGE THERAPY; T CELL LYMPHOMA; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT OUTCOME; UREMIA; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247198980     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601123989     Document Type: Article

References (23)

1. Frizzera, G., Moran, E. M. and Rappaport, H. (1974) Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet, 1, pp. 1070-1073.
2. Kaneko, Y., Maseki, N., Sakurai, M., Takayama, S., Nanba, K. and Kikuchi, M. (1988) Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive "angioimmunoblastic lymphadenopathy with dysproteinemia-type" features. Blood, 72, pp. 413-421.
3. Feller, A. C., Griesser, H., Schilling, C. V., Wacker, H. H., Dallenbach, F. and Bartels, H. (1988) Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol, 133, pp. 549-556.
4. Jaffe, E. S., Harris, N. L., Stein, H. and Vardiman, J. W. (2001) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, IARC Press, Lyon, France
5. Frizzera, G., Moran, E. M. and Rappaport, H. (1975) Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. Am J Med, 59, pp. 803-818.
6. Nathwani, B. N., Rappaport, H., Moran, E. M., Pangalis, G. A. and Kim, H. (1978) Malignant lymphoma arising in angioimmunoblastic lymphadenopathy. Cancer, 41, pp. 578-606.
7. Archimbaud, E., Coiffier, B., Bryon, P. A., Vasselon, C., Brizard, C. P. and Viala, J. J. (1987) Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer, 59, pp. 208-212.
8. Aozasa, K., Ohsawa, M., Fujita, M. Q., Kanayama, Y., Tominaga, N. and Yonezawa, T. (1989) Angioimmunoblastic lymphadenopathy. Review of 44 patients with emphasis on prognostic behavior. Cancer, 63, pp. 1625-1629.
9. Siegert, W., Agthe, A., Griesser, H., Schwerdtfeger, R., Brittinger, G., Engelhard, M. and for Kiel Lymphoma Study Group (1992) Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study group. Ann Intern Med, 117, pp. 364-370.
10. Ohsaka, A., Saito, K., Sakai, T., Mori, S., Kobayashi, Y. and Amemiya, Y. (1992) Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy-related lesions. Cancer, 69, pp. 1259-1267.
11. Tobinai, K., Minato, K., Ohtsu, T., Mukai, K., Kagami, Y. and Miwa, M. (1988) Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. Blood, 72, pp. 1000-1006.
12. Pangalis, G. A., Moran, E. M., Nathwani, B. N., Zelman, R. J., Kim, H. and Rappaport, H. (1983) Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer, 52, pp. 318-321.
13. Siegert, W., Nerl, C., Agthe, A., Engelhard, M., Brittinger, G., Tiemann, M. and for The Kiel Lymphoma Study Group (1995) Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. Ann Oncol, 6, pp. 659-664.
14. Pautier, P., Devidas, A., Delmer, A., Dombret, H., Sutton, L. and Zini, J. M. (1999) Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma, 32, pp. 545-552.
15. Kim, K., Kim, W. S., Jung, C. W., Im, Y. H., Kang, W. K. and Lee, M. H. (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer, 38, pp. 75-81.
16. Signoretti, S., Murphy, M., Cangi, M. G., Puddu, P., Kadin, M. E. and Loda, M. (1999) Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. Am J Pathol, 154, pp. 67-75.
17. Gallamini, A., Stelitano, C., Calvi, R., Bellei, M., Mattei, D. and Vitolo, U. (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood, 103, pp. 2474-2479.
18. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, p. 1244.
19. Julie, M. and Vose, J. M. (2005) International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: Poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood, 106, p. 811.
20. Kim, W. S., Song, S. Y., Ahn, Y. C., Ko, Y. H., Baek, C. H. and Kim, D. Y. (2001) CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol, 12, pp. 349-352.
21. Liang, R., Todd, D., Chan, T. K., Wong, K. L. and Loke, S. L. (1987) Peripheral T cell lymphoma. J Clin Oncol, 5, pp. 750-755.
22. Schetelig, J., Fetscher, S., Reichle, A., Berdel, W. E., Beguin, Y. and Brunet, S. (2003) Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica, 88, pp. 1272-1278.
23. Lee, J., Suh, C., Park, Y. H., Ko, Y. H., Bang, S. M. and Lee, J. H. (2006) Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol, 24, pp. 612-618.